ArticleiScience2025
C-reactive protein-albumin-lymphocyte index and atrial fibrillation recurrence after radiofrequency ablation in heart failure.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between microinflammatory state and cardiac valvular calcification in patients undergoing maintenance hemodialysis: a single-centre observational study.BMC nephrology · 2026Observational
- High CALLY index is independently associated with lower odds of preserved ratio impaired spirometry (PRISm) and provides incremental predictive value: a retrospective observational study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) frequently coexists with heart failure (HF), and predicting post-ablation recurrence remains challenging. This study evaluated the association between the C-reactive protein-albumin-lymphocyte (CALLY) index and post-ablation AF recurrence. We enrolled 159 patients who underwent first-time ablation. Over 12 months, 28.9% experienced recurrence. Associations were tested using Cox regression, Kaplan-Meier curves, restricted cubic splines (RCSs), receiver operating characteristic analysis, and subgroup analyses, with confirmation in an external cohort. Forty-six patients (28.9%) recurred. After multivariable adjustment, the highest CALLY index quartile had lower recurrence risk than the lowest (hazard ratio [HR] = 0.203; 95% confidence interval [CI]: 0.067-0.615;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.